RevenueNet IncomeP/EP/SEBITDividendStocksMarket capitalizationDebtLiabilitiesEquityAAQSEmployeesROEROAROCE

Hepion Pharmaceuticals ROE 2024

Hepion Pharmaceuticals ROE

-6.72

Hepion Pharmaceuticals Dividend yield

Ticker

HEPA

ISIN

US4268971045

WKN

A2PN6W

In 2024, Hepion Pharmaceuticals's return on equity (ROE) was -6.72, a 639.57% increase from the -0.91 ROE in the previous year.

Hepion Pharmaceuticals Aktienanalyse

What does Hepion Pharmaceuticals do?

Hepion Pharmaceuticals Inc. is a biopharmaceutical company focused on researching and developing therapeutics for the treatment of liver diseases. The company was founded in 2013 and is headquartered in Edison, New Jersey. The history of Hepion Pharmaceuticals Inc. began with the discovery of a new approach to treating liver diseases. Researchers found that small molecules targeting specific cells in the liver could have a positive effect on liver function. Hepion used this discovery as a starting point for developing new drugs to treat liver diseases. Hepion Pharmaceuticals Inc.'s business model is based on the development and marketing of innovative therapeutics for a variety of liver diseases, including fatty liver disease, alcoholic liver disease, non-alcoholic steatohepatitis (NASH), liver fibrosis, liver cirrhosis, and liver cancer. Hepion Pharmaceuticals has several divisions, all focused on the development of therapeutics for liver diseases. The primary division is research and development, which focuses on identifying and developing new drugs for the liver. Another important division is clinical development, where the drugs are tested and validated in clinical trials. The third division is marketing, where the therapeutics are marketed and sold. Hepion Pharmaceuticals Inc. currently offers two products. The first product is CRV431, a top-notch inhibitor of cytokine-mediated signaling. It is an orally administered drug specifically developed for the treatment of liver fibrosis. CRV431 aims to inhibit cytokine-mediated signaling responsible for fibrosis formation. The second product is an idiosyncratic database marketed under the name AI-Enabler. It is touted by the company as a groundbreaking tool for more precise medicine and research in support of drug development work. Overall, Hepion Pharmaceuticals Inc. is a promising biopharma company with a clear focus on developing new drugs for the treatment of liver diseases. With its innovative products and expertise in research and development, the company collaborates closely with partners from the scientific, industrial, and governmental sectors. It is hoped that this company will make further pioneering discoveries in the future and contribute to the benefit of human health. Hepion Pharmaceuticals ist eines der beliebtesten Unternehmen auf Eulerpool.com.

ROE Details

Decoding Hepion Pharmaceuticals's Return on Equity (ROE)

Hepion Pharmaceuticals's Return on Equity (ROE) is a fundamental metric evaluating the company's profitability relative to its equity. Calculated by dividing net income by shareholder's equity, ROE illustrates how effectively the company is generating profits from shareholders’ investments. A higher ROE represents enhanced efficiency and profitability.

Year-to-Year Comparison

Analyzing Hepion Pharmaceuticals's ROE on a yearly basis aids in tracking its profitability trends and financial performance. An increasing ROE suggests enhanced profitability and value generation for shareholders, whereas a declining ROE may indicate issues in profit generation or equity management.

Impact on Investments

Hepion Pharmaceuticals's ROE is instrumental for investors assessing the company's profitability, efficiency, and investment attractiveness. A robust ROE indicates the firm’s adeptness at converting equity investments into profits, thereby enhancing its appeal to potential and current investors.

Interpreting ROE Fluctuations

Changes in Hepion Pharmaceuticals’s ROE can emanate from variations in net income, equity capital, or both. These fluctuations are scrutinized to evaluate management’s effectiveness, financial strategies, and the inherent risks and opportunities, aiding investors in making informed decisions.

Frequently Asked Questions about Hepion Pharmaceuticals Stock

What is the ROE (Return on Equity) of Hepion Pharmaceuticals this year?

The ROE of Hepion Pharmaceuticals this year is -6.72 undefined.

How has the Return on Equity (ROE) of Hepion Pharmaceuticals developed compared to the previous year?

The ROE of Hepion Pharmaceuticals has increased by 639.57% increased compared to the previous year.

What impact does a high ROE (Return on Equity) have on investors of Hepion Pharmaceuticals?

A high ROE indicates that Hepion Pharmaceuticals generates good returns on capital and is successful in monetizing its investments. This is a positive indicator for investors.

What impact does a low ROE (Return on Equity) have on investors of Hepion Pharmaceuticals?

A low ROE can indicate that Hepion Pharmaceuticals is having difficulties monetizing its investments successfully and can be a negative signal for investors.

How does a change in the ROE (Return on Equity) of Hepion Pharmaceuticals affect the company?

A change in ROE (Return on Equity) of Hepion Pharmaceuticals can be an indicator of the financial performance of the company and demonstrate how successful the company is compared to other companies in the same industry.

How to calculate the ROE (Return on Equity) of Hepion Pharmaceuticals?

The ROE (Return on Equity) is calculated by dividing the company's profit by the total equity. The formula is: ROE = Profit / Total equity.

Which factors influence the ROE (Return on Equity) of Hepion Pharmaceuticals?

Some factors that can influence Hepion Pharmaceuticals's Return on Equity (ROE) include the efficiency in using equity, the profitability of the company, and the financing structure.

What strategic measures can take to improve the ROE (Return on Equity)?

To improve the Return on Equity (ROE), can take measures such as cost savings, increasing revenue, improving efficiency in the use of equity, and making changes in the financing structure. It is important for the company to conduct a thorough review of its financial situation to determine the best strategic actions to improve ROE.

How much dividend does Hepion Pharmaceuticals pay?

Over the past 12 months, Hepion Pharmaceuticals paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Hepion Pharmaceuticals is expected to pay a dividend of 0 USD.

What is the dividend yield of Hepion Pharmaceuticals?

The current dividend yield of Hepion Pharmaceuticals is .

When does Hepion Pharmaceuticals pay dividends?

Hepion Pharmaceuticals pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Hepion Pharmaceuticals?

Hepion Pharmaceuticals paid dividends every year for the past 0 years.

What is the dividend of Hepion Pharmaceuticals?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is Hepion Pharmaceuticals located?

Hepion Pharmaceuticals is assigned to the 'Health' sector.

Wann musste ich die Aktien von Hepion Pharmaceuticals kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Hepion Pharmaceuticals from 5/23/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 5/23/2024.

When did Hepion Pharmaceuticals pay the last dividend?

The last dividend was paid out on 5/23/2024.

What was the dividend of Hepion Pharmaceuticals in the year 2023?

In the year 2023, Hepion Pharmaceuticals distributed 0 USD as dividends.

In which currency does Hepion Pharmaceuticals pay out the dividend?

The dividends of Hepion Pharmaceuticals are distributed in USD.

Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

The Hepion Pharmaceuticals stock can be added to a savings plan with the following providers: Trade Republic

Andere Kennzahlen von Hepion Pharmaceuticals

Our stock analysis for Hepion Pharmaceuticals Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Hepion Pharmaceuticals Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.